Moscarella, Elisabetta and Ielasi, Alfonso and Kim, Won-Keun and Caminiti, Rodolfo and Barbanti, Marco and Giordano, Arturo and Holzamer, Andreas and Testa, Luca and Adamo, Marianna and Eitan, Amnon and Estevez-Loureiro, Rodrigo and Farkic, Mihajlo and Stoyanov, Nikolay and Leick, Juergen and Kovacevic, Mila and Tigges, Eike and Mangieri, Antonio and Scotti, Andrea and Latib, Azeem (2025) Balloon-Expandable Myval Octacor Versus Self-Expanding Evolut PRO/PRO plus and Acurate Neo2: Short-Term Outcomes From Propensity-Matched Analysis. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 106 (5). pp. 2949-2957. ISSN 1522-1946, 1522-726X
Full text not available from this repository. (Request a copy)Abstract
Background With transcatheter aortic valve implantation (TAVI) now extending to lower-risk and younger patients, optimizing procedural and hemodynamic outcomes is critical. The Myval Octacor, a new balloon-expandable valve (BEV), was developed to improve outcomes by reducing paravalvular regurgitation (PVL), minimizing pacemaker implantation (PPI) rates, and enhancing hemodynamic performance. However, limited data are available comparing Myval Octacor to contemporary self-expanding supra-annular valves (SEVs) Evolut PRO/PRO+ and Acurate Neo2.Aims This study aimed to compare the safety, efficacy, and short-term clinical outcomes of Myval Octacor with SEVs in transfemoral TAVI patients.Methods We conducted a prospective, multicenter registry including patients treated with Myval Octacor, then compared them to SEV recipients from the NEOPRO2 registry. Propensity score matching adjusted for baseline differences between groups. The primary endpoint was 30-day Valve Academic Research Consortium-3 (VARC-3) device success. Secondary endpoints included technical success, valve performance, and early safety outcomes.Results Among 252 Myval Octacor patients and 2175 SEV patients, 90 matched pairs were compared. Myval Octacor patients showed higher 30-day VARC-3 device success than SEVs patients (97% vs. 88%, p = 0.024), primarily due to a numerically lower rate of moderate-to-severe PVL (1% vs. 7%, p = 0.06). The Octacor group also exhibited larger indexed effective orifice areas. Mortality, stroke, PPI, and myocardial infarction rates were similar between groups at 30 days.Conclusions The Myval Octacor demonstrated comparable early safety and efficacy to supra-annular SEVs, with advantages in device success rate and hemodynamic performance. Adequately sized randomized study is required to confirm these findings.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PERMANENT PACEMAKER IMPLANTATION; TRANSCATHETER HEART-VALVE; NATIVE AORTIC-STENOSIS; PREDICTORS; REGURGITATION; REPLACEMENT; aortic stenosis; balloon-expandable Myval; self-expanding Acurate Neo2; self-expanding Evolut PRO/PRO plus; transcatheter aortic valve replacement; transcatheter heart valves |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Herz-, Thorax- und herznahe Gefäßchirurgie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 20 Apr 2026 12:40 |
| Last Modified: | 20 Apr 2026 12:40 |
| URI: | https://pred.uni-regensburg.de/id/eprint/67610 |
Actions (login required)
 |
View Item |
